@article{3191420,
    title = "Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review
and Implications for Future Research",
    author = "Bikdeli, Behnood and Madhavan, Mahesh V. and Gupta, Aakriti and Jimenez, and David and Burton, John R. and Nigoghossian, Caroline Der and Chuich, and Taylor and Nouri, Shayan Nabavi and Dreyfus, Isaac and Driggin, Elissa and and Sethi, Sanjum and Sehgal, Kartik and Chatterjee, Saurav and Ageno, and Walter and Madjid, Mohammad and Guo, Yutao and Tang, Liang V. and Hu, Yu and and Bertoletti, Laurent and Giri, Jay and Cushman, Mary and Quere, and Isabelle and Dimakakos, Evangelos P. and Gibson, C. Michael and Lippi, and Giuseppe and Favaloro, Emmanuel J. and Fareed, Jawed and Tafur, Alfonso and J. and Francese, Dominic P. and Batra, Jaya and Falanga, Anna and and Clerkin, Kevin J. and Uriel, Nir and Kirtane, Ajay and McLintock, Claire and and Hunt, Beverley J. and Spyropoulos, Alex C. and Barnes, Geoffrey D. and and Eikelboom, John W. and Weinberg, Ido and Schulman, Sam and Carrier, and Marc and Piazza, Gregory and Beckman, Joshua A. and Leon, Martin B. and and Stone, Gregg W. and Rosenkranz, Stephan and Goldhaber, Samuel Z. and and Parikh, Sahil A. and Monreal, Manuel and Krumholz, Harlan M. and and Konstantinides, Stavros V. and Weitz, Jeffrey I. and Lip, Gregory Y. H. and and Global COVID-19 Thrombosis Collabo",
    journal = "Thrombosis and Haemostasis",
    year = "2020",
    volume = "120",
    number = "07",
    pages = "1004-1024",
    publisher = "Georg Thieme Verlag KG",
    issn = "0340-6245",
    doi = "10.1055/s-0040-1713152",
    keywords = "coronavirus disease 2019; thrombosis; inflammation; fibrinolytic
therapy; anticoagulation; immunomodulator; antithrombin; thrombomodulin",
    abstract = "Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is
a viral illness caused by the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic
events to morbidity and mortality in COVID-19 patients has prompted a
search for novel potential options for preventing COVID-19-associated
thrombotic disease. In this article by the Global COVID-19 Thrombosis
Collaborative Group, we describe novel dosing approaches for commonly
used antithrombotic agents (especially heparin-based regimens) and the
potential use of less widely used antithrombotic drugs in the absence of
confirmed thrombosis. Although these therapies may have direct
antithrombotic effects, other mechanisms of action, including
anti-inflammatory or antiviral effects, have been postulated. Based on
survey results from this group of authors, we suggest research
priorities for specific agents and subgroups of patients with COVID-19.
Further, we review other agents, including immunomodulators, that may
have antithrombotic properties. It is our hope that the present document
will encourage and stimulate future prospective studies and randomized
trials to study the safety, efficacy, and optimal use of these agents
for prevention or management of thrombosis in COVID-19."
}